AR123977A1 - 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr - Google Patents
1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfrInfo
- Publication number
- AR123977A1 AR123977A1 ARP210103034A ARP210103034A AR123977A1 AR 123977 A1 AR123977 A1 AR 123977A1 AR P210103034 A ARP210103034 A AR P210103034A AR P210103034 A ARP210103034 A AR P210103034A AR 123977 A1 AR123977 A1 AR 123977A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 4alkyl
- group
- 6haloalkyl
- membered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20205297 | 2020-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123977A1 true AR123977A1 (es) | 2023-02-01 |
Family
ID=73059474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103034A AR123977A1 (es) | 2020-11-02 | 2021-11-01 | 1h-pirazolo[4,3-c]piridinas sustituidas y derivados como inhibidores de egfr |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12064421B2 (OSRAM) |
| EP (1) | EP4237423B1 (OSRAM) |
| JP (1) | JP7805363B2 (OSRAM) |
| CN (1) | CN116507627B (OSRAM) |
| AR (1) | AR123977A1 (OSRAM) |
| TW (1) | TW202233637A (OSRAM) |
| WO (1) | WO2022090481A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| KR20240133663A (ko) * | 2023-02-28 | 2024-09-04 | 보로노이 주식회사 | 헤테로아릴 유도체 및 이의 용도 |
| KR20240152239A (ko) * | 2023-04-11 | 2024-10-21 | 보로노이 주식회사 | 피라졸로피리딘 유도체 화합물 및 이의 용도 |
| CN117069746B (zh) * | 2023-08-17 | 2025-10-21 | 苏州共康医药科技有限公司 | 取代的吡唑并吡啶类化合物作为4代egfr抑制剂 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7338959B2 (en) | 2002-03-01 | 2008-03-04 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| JP2006528702A (ja) | 2003-05-21 | 2006-12-21 | プロシディオン・リミテッド | グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター |
| WO2006053166A1 (en) | 2004-11-12 | 2006-05-18 | Bristol-Myers Squibb Company | 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| JP2010517970A (ja) | 2007-02-02 | 2010-05-27 | ノイロサーチ アクティーゼルスカブ | ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用 |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2013056679A1 (en) | 2011-10-21 | 2013-04-25 | Beijing Hanmi Pharmaceutical Co., Ltd | Novel heteroaryl-amino derivatives |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| WO2013184766A1 (en) | 2012-06-06 | 2013-12-12 | Irm Llc | Compounds and compositions for modulating egfr activity |
| CA2871388A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | 5-azaindazole compounds and methods of use |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| MX2016002241A (es) | 2013-08-22 | 2016-05-31 | Hoffmann La Roche | Alcoholes de alquinilo y metodos de uso. |
| CN104418858B (zh) | 2013-08-30 | 2018-12-11 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用 |
| US9546168B2 (en) | 2013-12-18 | 2017-01-17 | Merck Sharp & Dohme Corp. | ERK inhibitors |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| CA3175724C (en) | 2014-03-20 | 2024-01-09 | Capella Therapeutics, Inc. | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof |
| TWI705967B (zh) | 2014-03-20 | 2020-10-01 | 美商卡佩拉醫療公司 | 苯并咪唑衍生物及其醫藥組合物及使用方法 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN108012529A (zh) | 2015-05-15 | 2018-05-08 | 诺华股份有限公司 | 治疗egfr突变的癌症的方法 |
| EP3303334B1 (en) | 2015-06-03 | 2021-06-02 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CA2987914C (en) | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| KR20180051624A (ko) | 2015-09-11 | 2018-05-16 | 베링거 인겔하임 인터내셔날 게엠베하 | 피라졸릴 치환된 헤테로아릴 및 의약으로서의 이의 용도 |
| TWI726968B (zh) * | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| SG11201903871TA (en) | 2016-11-03 | 2019-05-30 | Bristol Myers Squibb Co | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
| CA3061053A1 (en) | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| PH12020550725B1 (en) | 2017-12-02 | 2024-05-24 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2019162323A1 (en) * | 2018-02-21 | 2019-08-29 | Boehringer Ingelheim International Gmbh | New benzimidazole compounds and derivatives as egfr inhibitors |
| WO2020178316A1 (en) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | 5- or 7-azaindazoles as beta-lactamase inhibitors |
-
2021
- 2021-10-29 EP EP21799061.3A patent/EP4237423B1/en active Active
- 2021-10-29 WO PCT/EP2021/080151 patent/WO2022090481A1/en not_active Ceased
- 2021-10-29 US US17/514,145 patent/US12064421B2/en active Active
- 2021-10-29 JP JP2023526609A patent/JP7805363B2/ja active Active
- 2021-10-29 CN CN202180073462.4A patent/CN116507627B/zh active Active
- 2021-11-01 TW TW110140534A patent/TW202233637A/zh unknown
- 2021-11-01 AR ARP210103034A patent/AR123977A1/es not_active Application Discontinuation
-
2024
- 2024-06-27 US US18/756,533 patent/US20240358688A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4237423B1 (en) | 2024-12-11 |
| US20240358688A1 (en) | 2024-10-31 |
| WO2022090481A1 (en) | 2022-05-05 |
| US20220133734A1 (en) | 2022-05-05 |
| JP7805363B2 (ja) | 2026-01-23 |
| US12064421B2 (en) | 2024-08-20 |
| EP4237423A1 (en) | 2023-09-06 |
| CN116507627B (zh) | 2026-01-23 |
| TW202233637A (zh) | 2022-09-01 |
| CN116507627A (zh) | 2023-07-28 |
| JP2023550591A (ja) | 2023-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR108396A1 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR128211A1 (es) | Composiciones y métodos para la inhibición de ras | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR126108A1 (es) | Tratamientos para la degradación del braf mutante | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR093339A1 (es) | Analogos de spliceostatina y metodos para su preparacion | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR104513A1 (es) | Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2 | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR119244A1 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| AR098492A1 (es) | Derivados de purina | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR120800A1 (es) | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr | |
| AR105460A1 (es) | Derivados sustituidos de 2-pirimidina furano / tienocicloalquilamino y su uso para el control del crecimiento de plantas no deseables | |
| AR115898A1 (es) | 1,7-naftiridinas como inhibidores de cdk8/19 | |
| AR124451A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |